PP1 - CAS:172889-26-8 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	PP1 促销
英文名称:	PP1
别名:	蛋白磷酸酯酶-1(抗原) AGL 1872; EI 275
CAS No:	172889-26-8	分子式:	C₁₆H₁₉N₅	分子量:	281.36
CAS No:	172889-26-8
分子式:	C₁₆H₁₉N₅
分子量:	281.36
MDL:	MFCD01076570

安全技术说明书(PDF) MSDS(PDF) 点击下载技术规格说明书(PDF) 点击下载产品说明书(PDF)

P10805 PP1 ≥98% (psaitong)

相关产品

CpCDPK1/TgCDPK1-IN-1
CAS No：1092788-23-2
4-氨基1-叔丁基-3-(1'-萘甲基)吡唑并[3,4-D]嘧啶
CAS No：221244-14-0
4-氨基1-叔丁基-3-(1'-萘甲基)吡唑并[3,4-D]嘧啶
CAS No：221244-14-0
HIV-IN-6
CAS No：301357-74-4
RK 24466
CAS No：213743-31-8
TG53
CAS No：946369-04-6

包装规格：

5mg 25mg 100mg in glass bottle

溶解性：

溶于DMSO（28 mg/mL 超声）

产品描述：

基本信息

产品编号：P10805
产品名称：PP1
CAS:	172889-26-8	储存条件	粉末	-20℃	四年

分子式：	C16H19N5		溶于液体	-80℃	六个月
分子量	281.36			-20℃	一个月
化学名：
Solubility (25°C)	体外	DMSO	5mg/mL (17.77mM)
		Ethanol	Insoluble
		Water	Insoluble
	体内（现配现用）
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	3.5542mL	17.7708mL	35.5417mL
5mM	0.7108mL	3.5542mL	7.1083mL
10mM	0.3554mL	1.7771mL	3.5542mL

生物活性

产品描述

一种有效的选择性 Src 家族抑制剂，抑制 Lck 和 Fyn，IC50 分别为 5 和 6nM。

靶点/IC50

IC50: 5nM (Lck), 6nM (Fyn), 250 nM (EGFR), >50μM (JAK2

体外研究

PP1 inhibits Lck (IC50=5nM) and FynT (IC50=6nM) in vitro at concentrations significantly lower than those required to inhibit ZAP-70 (IC50>100μM), JAK2 (IC50>50μM), the EGFR kinase, and protein kinase A. PP1 inhibits whole cell tyrosine phosphorylation and proliferation in T cells stimulated with anti-CD3 and mitogens. PP1 selectively inhibits IL-2 gene expression over GM-CSF and IL-2R gene induction in human T cells.

推荐实验方法(仅供参考)

激酶实验：

Protein A-Sepharose beads (prepared as a 50% (w/v) suspension) are added to the antibody/lysate mixture at 250μL/mL and allowed to incubate for 30 min at 4°C. The beads are then washed twice in 1mL of lysis buffer and twice in 1 mL of kinase buffer (25 mM HEPES, 3mM MnCl2, 5mM MgCl2, and 100μM sodium orthovanadate) and resuspended to 50% (w/v) in kinase buffer. Twenty-five microliters of the bead suspension is added to each well of the enolase-coated 96-well high protein binding plate together with an appropriate concentration of compound and [γ-32P]ATP (25μL/well of a 200μCi/mL solution in kinase buffer). After incubation for 20 min at 20°C, 60μL of boiling 2× solubilization buffer containing 10mM ATP is added to the assay wells to terminate the reactions. Thirty microliters of the samples is removed from the wells, boiled for 5 min, and run on a 7.5% SDS-polyacrylamide gel. The gels are subsequently dried and exposed to Kodak X-AR film. For quantitation, films are scanned using a Molecular Dynamics laser scanner, and the optical density of the major substrate band, enolase p46, is determined. Concentrations of compound that causes 50% inhibition of enolase phosphorylation (IC50) are determined from a plot of the density versus concentration of compound. In companion experiments for measuring the activity of compounds against Lck, the assay plate is washed with two wash cycles on a Skatron harvester using 50mM EDTA, 1mM ATP. Scintillation fluid (100μL) is then added to the wells,and P incorporation is measured using a Pharmacia Biotech micro-β-counter. Concentrations of compound that causes 50% inhibition of enzyme activity (IC50) are determined from a plot of the percent inhibition of enzyme activity versus concentration of compound.

细胞实验:

Inhibition of anti-CD3-stimulated tyrosine phosphorylation in purified human peripheral blood T cells is measured as follows. All incubations are carried out at 37°C in an Eppendorf Thermomixer 5436 at a mixing setting of 11. Cells (1×106 in 100 μL of RPMI 1640 medium) are incubated for 15 min with drug prior to a 6-min incubation with 1 μg of anti-CD3/mL (antileu4, 100μg/mL). The final volume of the reaction is 115μL.Reactions are terminated by the addition of 57.5μL of 3×solubilization buffer incubated at 100°C prior to its addition. Samples are mixed, boiled for 5 min, and stored at -70°C. Western blots of these cell lysates, run on 10% SDS-polyacrylamide gels, are probed with a polyclonal anti-phosphotyrosine antibody, and immune complexes are detected with I-labeled protein A (ICN). For quantitation, films are scanned using a Molecular Dynamics laser scanner, and the optical densities of the major substrate band, p70,are quantitated in the presence of anti-CD3 (in the presence and absence of drug).Percent inhibition is calculated as follows: (1-(p70 optical density units in presence of drug/p70 units in absence of drug))×100.IC50 equals the concentration of compound at which 50% inhibition is measured.

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

点击下载核磁/氢谱图谱(PDF)

点击下载高效液相/气相图谱(PDF)

搜索质检报告(COA)

参考文献 & 客户发表文献